Press release: Umeå, October 12, 2022. The Extraordinary General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”), today resolved to approve the Board of Directors’ resolution on a directed share issue of 2,601,732 new shares.

The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby the share capital increases by SEK 650,433.

The minutes from the EGM (in Swedish) will be available on Lipum’s website,

For further information please contact:

Einar Pontén, CEO
Mobile phone: +46 70 578 34 95

About Lipum

Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The Company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The Company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.